ENDRA Life Sciences (NDRA) Retained Earnings (2016 - 2026)

ENDRA Life Sciences has disclosed Retained Earnings across 11 years of filings, most recently posting -$111.8 million for Q1 2026.

• In Q1 2026, Retained Earnings fell 6.99% year-over-year to -$111.8 million; the TTM figure through Mar 2026 stood at -$111.8 million (down 6.99% YoY), while the FY2025 annual figure was -$110.5 million, down 6.79% from the prior year.
• Retained Earnings fell to -$111.8 million in Q1 2026, from -$110.5 million in the prior quarter.
• Over the last five years, Retained Earnings for NDRA reached as high as -$71.5 million in Q1 2022 and fell as low as -$111.8 million in Q1 2026.
• The 5-year median for Retained Earnings is -$94.7 million (2024), against an average of -$93.9 million.
• Annual changes were most pronounced in 2022 — Retained Earnings dropped 19.81% — and 2025, when it retreated 6.79%.
• A 5-year view of Retained Earnings shows it stood at -$81.9 million in 2022, then slipped by 12.29% to -$91.9 million in 2023, then declined by 12.52% to -$103.4 million in 2024, then dropped by 6.79% to -$110.5 million in 2025, then decreased by 1.19% to -$111.8 million in 2026.
• According to Business Quant data, Retained Earnings over the past three periods registered -$111.8 million, -$110.5 million, and -$107.3 million for Q1 2026, Q4 2025, and Q3 2025 respectively.